LAX.SH
BIOFIL CHEM & PHARMA LTD·Healthcare Companies·Pharmaceuticals & Biotechnology Companies
Price
30.26
-1.69%52W Range
Market Cap
₹49.24 Cr
Traded: ₹0.03 Cr (0.07%) 0.0x
Free Float: ₹26.16 Cr (0.13% of FF traded)
Volume · 60D trend
11.22 K 0.0x
Delivery: % 0.0x
View Delivery Data
Returns
Valuation
Business Strength
Growth (3Y CAGR)
Balance Sheet
Cash Position
Others
MTF Exposure Trend
60 sessions · funded amount, % of FF, daily delta
LAX.SH
Growth Trends
| Metric | 10Y | 5Y | 3Y | 1Y | TTM | Trend |
|---|---|---|---|---|---|---|
| Sales | +8.0% | -5.0% | -2.0% | -- | -15.0% | Stable |
| ROE | +7.0% | +6.0% | +7.0% | -- | -- | Stable |
| Return | +15.0% | -13.0% | -7.0% | -34.0% | -- | Stable |
| Profit | +14.0% | +18.0% | +71.0% | -- | +398.0% | Accelerating |
Quarterly Results
Revenue & Margin Trends
Annual
Quarterly
Balance Sheet Health
Leverage
Efficiency
Cash Position
Detailed Financials
Jun 2026PDF ↗ | Mar 2026PDF ↗ | Dec 2025PDF ↗ | Sep 2025PDF ↗ | Jun 2025PDF ↗ | Mar 2025PDF ↗ | Dec 2024PDF ↗ | Sep 2024PDF ↗ | Jun 2024PDF ↗ | Mar 2024PDF ↗ | Dec 2023PDF ↗ | Sep 2023PDF ↗ | Jun 2023PDF ↗ | Mar 2023PDF ↗ | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 12 | 8 | 1 | 14 | 6 | 8 | 14 | 2 | 8 | 15 | 5 | 17 | 2 | 14 |
| Expenses | 12 | 7 | 1 | 13 | 6 | 8 | 14 | 2 | 8 | 15 | 5 | 17 | 2 | 13 |
| Operating Profit | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -0 | 0 | 0 | 0 | 0 |
| OPM % | 1.1% | 5.7% | 10.5% | 0.9% | 0.2% | 1.3% | 2.2% | 5.0% | 3.7% | -0.3% | 3.8% | 1.4% | 17.3% | 3.0% |
| Other Income | 0 | 0 | 0 | 0 | 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit Before Tax | 0 | 0 | 0 | 0 | 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Tax % | 23.1% | 55.3% | 30.0% | 27.3% | 12.7% | 23.1% | 27.3% | 33.3% | 26.1% | 11.1% | 18.2% | 20.0% | 25.0% | 34.4% |
| Net Profit | 0 | 0 | 0 | 0 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Exceptional Items | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| EPS (Rs) | 0.1 | 0.1 | 0.1 | 0.1 | 1.5 | 0.1 | 0.1 | 0.0 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 |
| Sales Growth (YoY) | -- | -9.3% | -93.9% | 461.8% | -23.8% | -45.1% | 182.3% | -86.1% | 247.3% | 11.6% | 237.6% | 563.0% | -80.3% | 725.5% |
| Sales Growth (QoQ) | -- | 780.2% | -93.7% | 110.6% | -23.0% | -41.2% | 489.2% | -71.5% | -44.5% | 202.2% | -71.0% | 614.8% | -82.2% | -- |
| OP Growth (YoY) | 1300.0% | 290.9% | -71.0% | 0.0% | -96.8% | 375.0% | 63.2% | -50.0% | -26.2% | -109.8% | -- | -- | -- | -- |
| OP Growth (QoQ) | -67.4% | 377.8% | -25.0% | 1100.0% | -90.9% | -64.5% | 158.3% | -61.3% | 875.0% | -121.1% | -20.8% | -42.9% | 2.4% | -- |
| Profit Growth (YoY) | -- | 5.0% | -50.0% | 300.0% | 1317.7% | -20.0% | 77.8% | -83.3% | -29.2% | 19.1% | -10.0% | 140.0% | 14.3% | 800.0% |
| EPS Growth (YoY) | -- | 8.3% | -50.0% | 400.0% | 1380.0% | -20.0% | 66.7% | -85.7% | -33.3% | 15.4% | -- | -- | -- | -- |
| EPS Growth (QoQ) | -- | 160.0% | 0.0% | -96.6% | 1133.3% | 20.0% | 900.0% | -90.0% | -33.3% | 150.0% | -14.3% | -53.3% | 15.4% | -- |
| OP Margin | -- | 5.7% | 10.5% | 0.9% | 0.2% | 1.3% | 2.2% | 5.0% | 3.7% | -0.3% | 3.8% | 1.4% | 17.3% | 3.0% |
| Net Margin | -- | 2.8% | 9.3% | 0.6% | 37.5% | 2.4% | 1.1% | 0.8% | 2.0% | 1.6% | 1.8% | 0.7% | 9.9% | 1.5% |
| Material Cost % | -- | 87.0% | 41.0% | 97.0% | 92.0% | 92.0% | 95.0% | 82.0% | 91.0% | 97.0% | 89.0% | 96.0% | 67.0% | 94.0% |
| Employee Cost % | -- | 3.0% | 22.0% | 1.0% | 3.0% | 3.0% | 1.0% | 7.0% | 2.0% | 1.0% | 3.0% | 1.0% | 7.0% | 1.0% |
| P/S | 1.43 | 1.87 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| P/E | 100.87 | 19.09 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| P/B | 2.28 | 2.46 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
Exchange Filings
50Newspaper publication of Notice of 41st AGM through Video Conferencing (''''VC'''')/ Other Audio Visual Means (''''OAVM'''')
Submission of publication of Un-audited Financial Results in the Newspaper pursuant to Regulation 47 of SEBI (Listing Obligation and Disclosure Requirement) Regulations, 2015
Continuation of Directorship of Mr. Ashok Kumar Ramawat (DIN: 08818263) as a Non-executive Independent Director of the company, notwithstanding his attaining the age of 75 (Seventy Five )Years
Un-Audited Financial Results for the quarter ended 30th June 2026
Outcome of Board Meeting held on Tuesday 11th August, 2026 pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
Certificate under Regulation 74(5) of the Securities and Exchange Board of India (Depository and Participants) Regulations, 2018 for the quarter ended 30th June, 2026.
Closure of Trading Window for the quarter ended 30.06.2026
Submission of publication of Audited Financial Results in the Newspaper pursuant to Regulation 47 of SEBI (Listing Obligation and Disclosure Requirement) Regulations, 2015
Audited Financial Result for the Financial Year ended 31.03.2026
Outcome of Board Meeting held on Saturday 30th May, 2026 pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
Submission of Annual Secretarial Compliance Report for the Financial year ended 31st March 2026
Biofil Chemicals & Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 30/05/2026 ,inter alia, to consider and approve the Audited ....
The Company hereby submit drafts intimation letter sent to holders of Physical shares of the company for updating PAN, KYC, Nomination and other details in accordance with applicable SEBI ....
<b>Format of Initial Disclosure to be made by an entity identified as a Large Corporate.</b><br/><br/> <table border=''1px''><tr> <td><b>Sr. No.</b></td> <td><b>Particulars</b></td> <td><b>Details</b></td> ....
Submission of Publication in Newspaper pursuant to SEBI circular for Special Window for Transfer and Dematerialisation of Physcial Securities.
Intimation regarding SEBI Circular dated January 30, 2026-Ease of Doing Investment- Special Window for Transfer and Dematerilaisation of Physical Securities .
Certificate under Regulation 74(5) of the Securities and Exchange Board of India (Depository and Participants) Regulations, 2018 for the quarter ended on 31st March, 2026
Closure of Trading Window period for the quarter and financial year ended 31.03.2026
Submission of Publication of Un-audited Financial Results for the quarter and nine months ended on 31st December 2025 in the newspaper pursuant to Regulation 47 of SEBI( Listing Obligation ....
Un-Audited Financial Results of the Company for the quarter and nine month ended on 31st December, 2025
Outcome of Board Meeting held on Friday 13th February, 2026
Clarification on Price Movement
The Exchange has sought clarification from Biofil Chemicals & Pharmaceuticals Ltd on February 3, 2026 with reference to significant movement in price, in order to ensure that investors ....
Biofil Chemicals & Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/02/2026 ,inter alia, to consider and approve 1. the Un-Audited ....
Certificate under Regulation 74(5) of the Securities and Exchange Board of India (Depositories and Participants) Regulations, 2018 for the quarter ended on 31st December,2025
Intimation of closure of Trading window with effect from Thursday 01st January, 2026.
Receipt of Fine from BSE Limited
Receipt of Fine from National Stock Exchange.
Submission of Publication of Un-audited Financial Result in the Newspaper pursuant to Regulation 47 of SEBI (Listing Obligations and Disclosure Requirement) Regulations, 2015
To review, consider and approve the Standalone Unaudited Financial Results for the quarter and half year ended on 30th September 2025 along with Limited Review Report
To review, consider and approve the Standalone Unaudited Financial Results for the quarter and half year ended on 30th September 2025 along with Limited Review Report
Biofil Chemicals & Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/11/2025 ,inter alia, to consider and approve To consider ....
Certificate under Regulation 74(5) of the Securities and Exchange Board of India (Depositories and Participants) Regulations, 2018 for the quarter ended on 30th September, 2025.
Continuous Disclosure of following material events or information for which disclosure as required under sub-clause 7 of Part A Para A of Schedule III : 1. Confirmation of appointment ....
Intimation of closure of Trading Window with effect from Wednesday 01st October, 2025
Scrutinizer report with voting result
Scrutinizer report with voting result
Summary of Proceeding of 40th Annual General Meeting of the Company held on Saturday, 27th September, 2025 .
Submission of voting results of postal ballot and report of Scrutinizer
Pursuant to Regulation 30, 44 and 47 of SEBI(LODR) Regulations, 2015 and in compliance with Section 108 of the Companies Act, 2013 read with rule 20 of Companies (Management and Administration) ....
Information under Regulation 44 of SEBI (LODR) Regulation, 2015 and Section 108 of Companies Act, 2013 regarding Voting through Electronic mode for the 40th Annual General Meeting to be ....
Submission of Annual Report for the Financial Year 2024-25 pursuant to Regulation 34 of SEBI (Listing Obligation and Disclosure Requirement) Regulation, 2015
Intimation for Dispatch of Letter to those Shareholders whose e-mail addresses are not registered with company/ registrar & transfer agent/ depository participants
Submission of Notice of 40th AGM scheduled to be held on Saturday 27th September, 2025 at 03:00 P.M. (IST) through video conference (VC)/Other audio visual means (OAVM)
Appointment of Mr. Smitesh Shah (DIN: 00326182) as an Additional Director under the category of Promoter Non- Executive Non Independent Director of the Company
Newspaper publication of Notice of AGM through Video Conferencing (''''VC'''')/other Audio Visual Means (''''OAVM'''')
Appointment of Chairman
Appointment of Managing Director
Appointment of Secretarial Auditor
Re-appointment of Independent Director.